Beta 3 Agonist Treatment in Heart Failure

Exclusion Criteria

• •1. Unstable cardiac condition
• •2. Acute myocardial infarction (AMI) or revascularisation \< 3 month ago
• •3. Atrial fibrillation (for technical reasons in relation to imaging and HR reporting)
• •4. Uncorrected significant primary obstructive valve disease
• •5. Planned major surgery including cardiac revascularisation
• •6. Hemodynamically significant obstructive cardiomyopathy
• •7. Stroke with significant neurological deficit
• •8. Acute myocarditis or constrictive pericarditis
• •9. Symptomatic bradycardia or \> 1. degree AV-block unless the patient has a pacemaker
• •10. Clinically significant hepatic (transaminases or bilirubin x 3 above upper reference level) or renal (GFR\< 50 ml/min/1,73 m2) diseases
• •11. Heart failure due to uncorrected thyroid disease
• •12. Cardiac mechanical support
• •13. \< 6 months after CRT
• •14. Uncontrolled hypotension (defined as symptomatic systolic blood pressure \< 90 mmHg) - or hypertension (defined as systolic at 180 mmHg or above and/or diastolic blood pressure at 110 mmHg or below)
• •15. Body mass index (BMI) \> 35
• •16. Unable to give informed consent
• •17. Reduced compliance
• •18. All women of child bearing potential will be required to use adequate contraception
• •19. Pregnant or lactating women
• •20. Treatment with a tricyclic antidepressant or CYP2D6 substrates other than beta-blockers or treatment with digoxin.